Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [912]

Gynaecological cancers in the era of fertility preservation

Dr Fedro Peccatori - European Institute of Oncology, Milan, Italy

Gynaecological cancers in the era of fertility preservation ( Dr Fedro Peccatori - European Institute of Oncology, Milan, Italy )

I-SPY 2: Durvalumab in combination with olaparib and paclitaxel in high-risk...

Prof Lajos Pusztai - Yale Cancer Center, New Haven, USA

I-SPY 2: Durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer ( Prof Lajos Pusztai - Yale Cancer Center, New Haven, USA )

Using cancer research strategies to develop an anti-coronavirus vaccine

Dr Bernard Fox - Providence Cancer Institute, Portland, USA

Using cancer research strategies to develop an anti-coronavirus vaccine ( Dr Bernard Fox - Providence Cancer Institute, Portland, USA )

Managing Hodgkin lymphoma during the COVID-19 outbreak

Dr Anna Sureda - Hospitalet de Llobregat, Barcelona, Spain

Managing Hodgkin lymphoma during the COVID-19 outbreak ( Dr Anna Sureda - Hospitalet de Llobregat, Barcelona, Spain )

CARTs for the treatment of T-cell malignancies

Dr John DiPersio - Siteman Cancer Center, St. Louis, USA

CARTs for the treatment of T-cell malignancies ( Dr John DiPersio - Siteman Cancer Center, St. Louis, USA )

EV-103: Enfortumab vedotin plus pembrolizumab for locally advanced or...

Dr Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA

EV-103: Enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma ( Dr Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA )

KEYNOTE 199 cohorts 4 & 5: Enzalutamide and pembrolizumab for mCRPC

Dr Julie Graff - Oregon Health & Science University, Portland, USA

KEYNOTE 199 cohorts 4 & 5: Enzalutamide and pembrolizumab for mCRPC ( Dr Julie Graff - Oregon Health & Science University, Portland, USA )

BCG dosing for bladder cancer: Standard frequency schedule correct

Prof Oliver Grimm - Universitätsklinikum Jena, Jena, Germany

BCG dosing for bladder cancer: Standard frequency schedule correct ( Prof Oliver Grimm - Universitätsklinikum Jena, Jena, Germany )

RADVAX: Nivolumab / ipilimumab with SBRT for metastatic renal cell carcinoma

Dr Hans Hammers - UT Southwestern Medical Center, Dallas, USA

RADVAX: Nivolumab / ipilimumab with SBRT for metastatic renal cell carcinoma ( Dr Hans Hammers - UT Southwestern Medical Center, Dallas, USA )

Integrative molecular characterisation of S/R RCC to reveal determinants of...

Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA

Integrative molecular characterisation of S/R RCC to reveal determinants of poor prognosis and response to ICIs ( Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA )

Cytoreductive nephrectomy for mRCC treated with immune checkpoint inhibitors or...

Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA

Cytoreductive nephrectomy for mRCC treated with immune checkpoint inhibitors or targeted therapy ( Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA )

NEO-BLADE: Nintedanib or placebo with gemcitabine and cisplatin in locally...

Dr Syed Hussain - University of Sheffield, Sheffield, United Kingdom

NEO-BLADE: Nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer ( Dr Syed Hussain - University of Sheffield, Sheffield, United Kingdom )

More from ecancer